Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Alcon Raises Bid for STAAR Surgical; Large Shareholders Continue to Oppose Deal
Alcon reported Dec. 9 that it had amended its bid for phakic IOL maker STAAR Surgical, raising its offer to $30.75 per share in cash, up from $28 in August. The 9.8 increase did little to appease s...
CMS Finalizes 2.6 Percent Increase for ASCs, HOPDs in 2026
The Centers for Medicare and Medicaid Services (CMS) has finalized a 2.6 percent increase in fees for ASCs and HOPDs in 2026, the agency reported Nov. 21. The percentage represents an average acros...
US FDA Gives Green Light to Trial of EyeYon’s EndoArt Artificial Corneal Implant
Israel’s EyeYon Medical announced Dec. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of EndoArt, a syntheti...
Lenz Partner Lotus Pharmaceutical Submits NDA in Korea for Vizz Presbyopia Drop
Lenz Therapeutics announced Dec. 1 that its partner Lotus Pharmaceutical had submitted a new drug application (NDA) to South Korea’s Ministry of Food and Drug Safety seeking marketing approval for ...
Santen to Market Bayer’s Authorized Eylea Biosimilar in Japan After Drug Gains Coverage
Bayer’s authorized biosimilar of Eylea (aflibercept) has secured reimbursement in Japan, according to an announcement from commercial partner Santen on Dec. 5. Bayer received approval of the biosim...
US FDA Gives Green Light to Trial of Zhongmou’s Optogenetic Therapy for RP
China’s Zhongmou Therapeutics announced Nov. 27 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of ZM-02, t...
Alkeus Appoints Retina Specialist Carlos Quezada-Ruiz, MD, as Chief Medical Officer
Alkeus Pharmaceuticals announced Dec. 2 that it had appointed retina specialist Carlos Quezada-Ruiz, MD, as chief medical officer. He succeeds Seemi Khan, MD, MPH, MBA, who has taken the role of ch...
Kriya Appoints Greg Di Russo, MD, as Chief Medical Officer
Kriya Therapeutics announced Dec. 1 that it had appointed Greg Di Russo, MD, as chief medical officer. The Durham, North Carolina, company has a pipeline of gene therapy candidates for chronic cond...
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline
Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...
Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million
Iolyx Therapeutics announced Dec. 3 that it had granted rights worldwide, excluding Asia, to France’s Laboratoires Théa to develop and commercialize ILYX-002, an immune-modulating eye drop candidat...
Formosa Licenses Clobetasol Drops to Rxilient for Countries in Southeast Asia
Taiwan-based Formosa Pharmaceuticals announced Dec. 3 that it had agreed to license to Rxilient Medical exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammatio...
CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement
Oncologist Richard Pazdur, MD, is reportedly retiring from his role as the US FDA’s director of the Center for Drug Evaluation and Research (CDER) after less than a month in the job. The FDA announ...
Past News Stories
Clearside to Pursue Strategic Sale Through Chapter 11 Process
Clearside Biomedical announced Nov. 24 that it had filed for Chapter 11 bankruptcy protection and intended to pursue an auction and sale of its business. Clearside, of Alpharetta, Georgia, had repo...
Ocuvex Resubmits NDA to US FDA for Once-Daily Brimonidine Drop
India’s Sun Pharma Advanced Research Company (SPARC) announced Nov. 20 that its partner Ocuvex had resubmitted the new drug application to the US FDA for PDP-716, a once-daily eye drop formulation ...
RVL Pharmaceuticals, Maker of Upneeq, Appoints Lori Deo as CEO
RVL Pharmaceuticals, of Bridgewater, New Jersey, announced Nov. 24 that it had appointed Lori Deo as chief executive officer. Deo had served as executive chairwoman of the board prior to the appoin...
Visara Appoints Cadmus Rich, MD, MBA, as Chief Medical Officer
NovaBridge Biosciences announced Nov. 20 that its ophthalmic subsidiary, Visara, had appointed ophthalmologist Cadmus Rich, MD, MBA, as its chief medical officer (CMO). Visara acquired VIS-101, for...
Cure Blindness Project’s 2025 Holiday Catalog Encourages Shoppers to Give Gift of Sight
Cure Blindness Project on Nov. 18 launched its 2025 Holiday Gift Guide, which the group describes as giving shoppers a thoughtful, sustainable, and hassle-free charity gift option. The catalog offe...
Bascom Palmer Eye Institute Opens Location in Abu Dhabi
The Bascom Palmer Eye Institute, part of the University of Miami Health System, announced that it was opening its first international location in Abu Dhabi, United Arab Emirates, in November. The p...
Assistance Fund Charity Launches Aid Program for MacTel Treatment
The Assistance Fund, a charitable organization that helps patients facing high out-of-pocket medical costs, announced Nov. 3 a new financial aid program for people living with macular telangiectasi...
AAO Retina Sessions Delve into Wide-field Imaging, Diabetic Eye Disease, and More
Approximately 2,300 doctors attended the Retina Subspecialty Day at the 2025 AAO meeting, and many stayed to take part in retina sessions during the remaining days of the conference. Highlights of ...
Cartwheel to License ClearSight’s OTC Pink Eye Treatment
Cartwheel, of Boston, Massachusetts, reported Nov. 12 that it had signed a letter of intent to license ClearSight Therapeutics’ over-the-counter (OTC) pink eye treatment beginning in 2027. ClearSig...
Coave Unveils Lead Gene Therapy Program for Retinal Vascular Diseases
France’s Coave Therapeutics announced Nov. 14 the selection of its lead gene therapy program, CoTx-101, targeting retinal vascular diseases such as wet age-related macular degeneration and diabetic...
Curative Biotech Seeks Strategic Partner to Advance Metformin Eye Drops for AMD
Curative Biotechnology issued a letter to shareholders Nov. 18, outlining its plan to seek a strategic partner to advance the metformin-based eye drops it licensed from the National Eye Institute. ...
Xbrane Plans to Resubmit BLA to US FDA in March 2026 for Lucentis Biosimilar
Sweden’s Xbrane Biopharma announced Nov. 19 that it would resubmit the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA in March 2026. A complete response...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.